Ovarian Cancer
Morphotek initiates phase II clinical studies for Morab-003 in ovarian cancer
Published in Women's Health Weekly, July 6th, 2006
Morab-003 is a monoclonal antibody that targets the folate receptor alpha (FRA), a target over-expressed in over 90% of ovarian cancers and a number of other solid tumors. The antibody works via suppression of FRA-mediated signal transduction and induces tumor-specific cytotoxicity by both antibody dependent cellular and complement mediated immune-effector mechanisms.
The antibody has shown clinical activity in a phase I trial which was presented by investigators from the Memorial Sloan-Kettering Cancer Center at...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
More Articles from Women's Health Weekly
- Arthritis
Decline in physical functioning for women in midlife may begin earlier than expected - Cardiovascular Disease
Cardiac autonomic regulation may be positively affected by raloxifene - Cervical Cancer
Low podoplanin expression predicts poor prognosis in advanced-stage squamous cell carcinoma - HIV/AIDS Transmission
Single-dose nevirapine studies would enhance understanding of nevirapine-resistant HIV-1 - Uterine Cancer
Uterine serous papillary cancer may be diagnosed by elevated serum kallikrein 10 - Autoimmune Disease
Anticardiolipin detection in infants best assay to evaluate disappearance of maternal aPL - More from this issue of Women's Health Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
